This post was just published on ZYX Buy Change Alert. MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug. The new buy zone is $32 to $35.57. Recommended position size is 35% to 40%. The stock is trading at $38.40 as of this writing. What To Do Now
This post was just published on ZYX Buy Change Alert. Totally contrary to its prior statements, WBA has reduced the buyout price for RAD from $9 per share to $7 per share if fewer than 1000 stores are required to be divested and to $6.50 if 1200 stores are required for divesture. If
This post was just published on ZYX Buy Change Alert. This is a short-term trade, not an investment for aggressive traders as the risk of loss is high. Consider buying up to 20% of RAD in the zone of $6.00 to $6.70. Stop zone is $5.38 to $5.73. Target zone is $7.50
Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the
Here is the interview of Nigam Arora on gold by Business Standard, India’s second largest financial publication. India is often the largest or the second largest consumer of gold. Enjoy! Nigam Arora is a financial market expert forecasting market trends using algorithms. His famous ‘Arora report’ is widely followed. In
This post was just published on ZYX Buy Change Alert. Only 62 days ago our call was to buy ALIOY on a potential buyout. Average price is $45.57. This is the 121st buyout of our portfolio companies. Over the years, the long-time subscribers to The Arora Report have generated substantial wealth from so many
This post was published on ZYX Buy Change Alert. STX is a computer storage manufacturer. Of note is that the company has 6.93% dividend yield and the yield will be much higher if bought in the proposed buy zone. The company reported earnings significantly better than the whisper numbers. As we were writing a
Donald Trump is starting his first full week as U.S. president. Bearish investors have been out in full force, proclaiming, with high confidence, that it’s time to sell stocks. At the same time, bullish gurus are saying just the opposite. So who’s right? Let’s explore the answer. First, we need
This post was just published on ZYX Buy Change Alert. LABD is a triple leveraged inverse biotech ETF. In plain English, this is a highly leveraged call on biotechs and pharmaceuticals going down if Trump decides to negotiate drug prices. Due to the leveraged nature of LABD, the risk of loss is
Donald Trump’s inauguration speech Jan. 20 could be boiled down to: “I’m going to put America first.” As an American, I liked that theme. “Protection will lead to great prosperity and strength,” the newly installed President Trump said. He also remarked: “We will follow two simple rules: Buy American and